Milton Essex
AI thermal-imaging dx · Allergy & inflammation dx
Overview
Non-invasive AI thermal-imaging (SAFE) to read skin-test and inflammatory responses — reimagining allergy diagnostics.
What they do
Milton Essex S.A. is a Polish med-tech company developing non-invasive AI thermal-imaging diagnostics for allergy and inflammation. Its platform (branded around SAFE / SkinSENS) uses far-infrared (LWIR) hyperspectral imaging to automatically read the body's thermal and inflammatory response, with a flagship use case in reading skin allergy-test reactions without manual measurement.
Lead program & status
The lead product is the SkinSENS imaging system for in-vivo allergy diagnostics, which automates assessment of histamine-induced cutaneous reactions; the company has cited related US patent rights (e.g. US 10,238,300 B2) and described itself as addressing a niche with no direct automated competitor. Milton Essex debuted on Poland's NewConnect market on 17 December 2020. It has publicly reported progressing certification steps for the SkinSENS allergy-diagnostics product, and previously described an offshoot thermal-screening concept (FaceCOV) for fever detection developed with the Military University of Technology. Specific regulatory-clearance completion and clinical results were not confirmed in available sources and should be treated as in-progress.
Why it matters
Allergy skin testing is widely used but read manually and subjectively. Automated, non-invasive thermal imaging promises faster, more objective and reproducible reads, with potential to extend to broader inflammatory-response diagnostics.
FAQ
- What is the SAFE / SkinSENS platform?
- It is Milton Essex's non-invasive AI thermal-imaging system that uses far-infrared hyperspectral imaging to automatically read allergic and inflammatory responses, notably skin allergy-test reactions.
- Is Milton Essex publicly listed?
- Yes. It debuted on Poland's NewConnect market (part of the Warsaw Stock Exchange group) on 17 December 2020.
- What stage is the product at?
- The company has reported advancing certification of its SkinSENS allergy-diagnostics product; as of available sources the approval and clinical-validation steps appear to be in progress rather than fully completed.
Technology
Milton Essex works in AI-Driven Drug Discovery — Compressing years of trial-and-error chemistry into months of computation.
Read the AI-Driven Drug Discovery brief →Related companies
Company website / source ↗ Open the interactive map →
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.